 Home > Medical News > Medicines Company News > Chuangsheng Group announced that its new anti-PD-L1 and TGF-β bifunctional antibody drug TST005 has been approved by the U.S. FDA for clinical trials

Chuangsheng Group announced that its new anti-PD-L1 and TGF-β bifunctional antibody drug TST005 has been approved by the U.S. FDA for clinical trials

 Last Update: 2021-07-08
 Source: Internet
 Author: User

Tags

fc antibody

cancer cell culture

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Chuangsheng Group, an international biopharmaceutical company in the clinical stage with the ability to integrate the entire process of biopharmaceutical R&D, clinical and process development and production, today announced that its new anti-PD-L1 and TGF-β bifunctional antibody (TST005) new drug has been obtained The U.
S.
Food and Drug Administration (FDA) is licensed to carry out clinical trials
.

TST005 is a bifunctional antibody that simultaneously targets two pathways commonly used by cancer cells to escape immune suppression, namely transforming growth factor-β (TGF-β) and programmed cell death ligand-1 (PD-L1)
.

TST005 is composed of a high-affinity PD-L1 antibody and an engineered TGF-β receptor type II protein fused to its C-terminus

"TST005 is one of the few leading drug candidates targeting PD-L1/TGF-β dual-functional antibodies currently under clinical development in the world
.

" Shi Ming, Executive Vice President, Head of Global R&D and Chief Medical Officer of Chuangsheng Group Dr.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.